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Background: Green fluorescent protein (GFP) is a useful biomarker, widely used in biomedical research to track stem
cells after transplantation and/or to assess therapeutic transgene expression. However, both GFP and therapeutic gene
products themselves may be immunogenic to the recipient. The main aim of this study was to use animal models to
evaluate potential impact of GFP on the cell engraftment and to optimize tracking strategies prior to transplantation.
Results: By using a fluorescent imaging (FLI) system, we investigated the dynamic cell behavior of GFP-transduced
myoblasts in tibialis anterior (TA) muscles of immunocompetent mdx mice and immuno-compromised nude mice over
a period of three months. The results suggested an apparent underlying host immunorejection in the mdx mice.
Dystrophin immunostaining showed that the engraftment of wild type myoblasts was much more effective than
that of the GFP-labeled counterparts in the mdx mice, further confirming an antigen role of GFP in this process.
We tracked the GFP-transduced myoblasts in C57BL/6 mice and found GFP to be minimally immunogenic in
these animals, as indicated by the GFP signal maintaining a much stronger level than that found in mdx and BALB/c
mice at parallel time points. We also compared the in vivo cell behavior differences between myoblasts from virally
GFP-transduced and GFP transgenic mice. The latter displayed much better engraftment, as determined both
biomaging and histological observations.
Conclusions: Our results not only demonstrated the immunogenicity of GFP in immunocompetent mice, but
determined the optimized conditions for GFP-based in vivo stem cells tracking, that can potentially be extrapolated
to human biomedical research.
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Cell-based therapy in general and transplantation of
stem cells in particular, is considered one of the most
promising strategies for the treatment of several refrac-
tory diseases such as muscular dystrophies, neurodegen-
erative disorders or cardiac stroke. However, to date,
besides the hematopoietic stem cell transplantation, cel-
lular therapies are still far away from being routinely
used for clinical purposes [1-3], and further research is
needed to clearly define mechanisms of their pharma-
ceutical properties and fully understand their potential* Correspondence: xxu@bwh.harvard.edu
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unless otherwise stated.biological side effects. Therefore, there is a great need for
in vivo imaging methods to dynamically track the location,
survival and engraftment of transplanted cells [1,4-7].
GFP is a useful biomarker, widely used in different
kinds of tissues to specifically track transplanted cells’
fate and/or validate the expression of therapeutic trans-
genes. In the past few years, advances in the field of
optical molecular imaging expedited the use of GFP in
broader areas of biomedical research [8-11]. Unfortu-
nately, an unavoidable problem of this technique is the
immunogenicity of GFP itself that has been described by
several reports [12-15]. It is essential to be able to track
and assess the engraftment of transplanted stem cells, as
their properties and differentiation can be easily affected
by multiple factors [1,8,16,17]. Even in a case of fully his-
tocompatible or gene-modified autologous transplantation,d. This is an Open Access article distributed under the terms of the Creative
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munogenic to the host, requiring administration of im-
munosuppressants [18-20]. As suggested by the previous
studies in the field of tumor cell immunological rejection,
the ideal transplantation host should be immunocompe-
tent, with minimal immune response to the GFP reporter
so as to obtain a better fluorescent signal [21,22]. The
main objective of our study was to evaluate the immuno-
genic effect of GFP in several animal models, and to de-
termine optimal conditions for GFP-based in vivo stem
cells tracking.
Molecular imaging techniques offer a platform that
can be used to monitor labeled transplanted cells in liv-
ing animal not only non-invasively but also continuously
and quantitatively. One of the clear advantages in using
GFP as a biomarker for optical molecular imaging is that
GFP-labeled cells can be directly examined under a
fluorescent microscope after tissue harvest. In general,
there are two main sources of the GFP-labeled cells: pri-
mary cultured cells that are retrovirally GFP-transduced
ex vivo, and cells directly isolated from GFP-transgenic
animals. So far, both of these sources of GFP-labeled
cells are widely used for in vivo cell tracking and optical
imaging [23-25]. However, for the same type of tissue
stem cells, it remains unclear whether some observed
discrepancies are a result of the different origin of GFP-
labeled cells used, and whether one source should be
preferentially chosen in the tracking experiments.
Myoblast transplantation is a cell-based therapy that
aims to restore the normal structure of pathogenic
muscle and to provide a source of stem cells for muscle
repair, and is regarded as a unique way to deliver genes
for therapeutic purposes [26,27]. In the present study,
we used the fluorescent imaging in combination with
histological observation to show that GFP plays a critical
role in the immunorejection response to transplanted
GFP-labeled myoblasts. Several animal models were used
in this study, including the mdx mouse model for the
Duchenne’s muscular dystrophy, that carries the muta-
tion within the dystrophin gene [28], as well as the im-
munodeficient nude, wild-type BALB/c and C57BL/6
mouse model. We found that the C57BL/6 mouse was a
better host candidate than other strains for GFP-labeled
myoblasts transplantation because of its minimal im-
munogenic response to GFP. We demonstrated that
GFP-transduced myoblasts possess myogenic differenti-
ation potential and re-enter the satellite niche after trans-
plantation. We also showed that the myoblasts from the
GFP transgenic mouse display much more effective en-
graftment capability compared to ex vivo GFP-transduced
ones. We believe that determining optimal conditions for
GFP-based in vivo stem cells tracking may potentially con-
tribute to further development of effective cell-based ther-
apies in human subjects.Methods
Animals
Imaging experiments used nude, mdx, C57BL/6, and
BALB/c WT mice that were obtained from Charles River
Laboratories. C57BL/Ka-β-actin-EGFP mice were a gift
from A Wagers. The GFP transgenic-mdx hybrid strain
was obtained by crossing the male mdx mice with female
C57BL/Ka-β-actin-EGFP mice. Genotyping of dystrophin
and GFP were performed using PCR (polymerase chain
reaction). Adult (6–8 weeks) male mice were used in the
study. All animal experimental manipulations were con-
ducted in accordance with a protocol approved by the
Institutional Animal Care and Use Committee of Harvard
Medical School.
Isolation of primary myoblasts and stable transduction of
eGFP gene
The primary myoblasts were isolated from the leg mus-
cles of adult C57BL/10 (an inbred substrain of C57BL/6)
or C57BL/Ka-β-actin-EGFP mice using the protocol de-
scribed by Rando and Blau [29]. After verifying their
myogenic identity using immunocytochemistry with an
anti-desmin antibody (1:200 dilution, Abcam Biochemicals,
Cambridge, MA, USA), myoblasts from C57BL/10 were
infected with eGFP-expressing lentiviral vectors. The
eGFP-expressing myoblasts were cultured in Ham's F10
medium (Life Technologies, Carlsbad, CA, USA) supple-
mented with 20% of fetal calf serum (Life Technologies,
Carlsbad, CA, USA) and 5 ng/ml basic fibroblast growth
factor (Sigma, St Louis, MO, USA). Before cell trans-
plantation, the eGFP expression in the myoblasts was
verified using a fluorescence microscope. Cell were tryp-
sinized, and after three washes with phosphate-buffered
saline and the determination of cell number, the final cell
pellet was suspended in Hanks solution to a final density
of 2 × 107–4 × 107 cells/ml.
Myoblasts transplantation
Six to eight week-old male mice were anesthetized by a
cocktail of ketamine and xylazine in saline (100 mg/
15 mg in 5 ml saline) at a dosage of 100 μl/20 g of body
weight. The mouse was placed in a prone position. Non-
nude mice leg hair was removed using Nair, a com-
mercially available hair remover (Church & Dwight,
Princeton, NJ, USA), and then the leg was wiped with
cotton swap dipped in clean water. Using a Hamilton syr-
inge, a total of 5 × 105 eGFP-labeled myoblasts in 20 μl
of Hanks were evenly injected at three positions along
the axis of tibialis anterior (TA) muscle. After cell injec-
tion, the needle was slowly withdrawn in 3 minutes.
Fluorescence imaging station
We used a planar fluorescence imaging station, NightOwl
LB981 (Berthold Technologies USA, LLC., Oak Ridge, TN),
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software toolbox, WinLight 3.2, to process the images.
The imaging station features a charge-coupled device
(CCD) camera of high sensitivity that can be moved
in a vertical direction for optimal focus. The imaging
chamber is light-tight to reduce background noise.
For the imaging of eGFP, an illumination light source
passes through a band-pass filter with a central wave-
length of 475 nm to excite the protein, and a band-pass
detection filter with a central wavelength of 525 nm se-
lectively captures the emission light of the excited eGFP.
The excitation and detection filters have a full-width half
magnitude of 40 and 10 nm, respectively. Light photo-
graphs of the subjects can be taken by switching off the
detection filter.
Imaging procedure and quantification of imaging data
Mice were anesthetized using the protocol described
above. Non-nude mice leg hair was removed using Nair
as described above. Each mouse was placed in a prone pos-
ition on a piece of nonfluorescent black paper (Strathmore
Series 400). To ensure that TA muscles were imaged in
the same position, both legs were positioned 180° apart
from each other and 90° relative to the body axis. Both
feet were taped to the paper with their dorsal sides up.
The CCD camera was set for a field of view of 6.5 cm2
with an estimated specimen height of 0.9 cm. A photo-
graphic picture was taken at an exposure time of 10 sec-
onds followed by a fluorescence image at an exposure
time of 1,250 ms.
We quantified the measurements with both the nor-
malized photon counts and the area of eGFP signals.
The region of interest (ROI) containing eGFP+ signal in
the fluorescence images was outlined manually, and then
the intensity (photon counts/second/mm2) of the ROI as
well as the area of the ROI was recorded. To normalize
the fluorescent signal from autofluorescence, we also
measured the intensity of an adjacent eGFP− region. We
then subtracted the photon counts/second/mm2 of ROI
by the photon counts/second/mm2 of the eGFP−area and
calculated the total photon counts generated by eGFP+
cells by timing the normalized intensity within the area of
the eGFP+ region.
Muscle harvest, histology and immunohistochemistry
staining
Mice were anesthetized with xylazine and ketamine as
described above and had their left ventricles perfused
with 4% (w/v) paraformaldehyde (PFA, Sigma, St Louis,
MO, USA) in phosphate-buffered saline (PBS) (pH 7.4).
The TA muscles were then carefully removed. Tissues
were post-fixed in 4% PFA over 12 hours, submersed in
30% sucrose overnight, frozen in OCT embedding com-
pound, and sectioned coronally (10 microns) with acryostat. Cryo-sections were thaw mounted onto gelatin-
coated slides and stored at -20°C.
Frozen sections, after being rinsed three times in PBS,
were permeabilized and blocked with PBS containing
0.1% (v/v) Triton X-100 and 10% (v/v) goat serum in
PBS for 1 hr at room temperature (RT) and then incu-
bated with either rabbit-anti-dystrophin antibody (1:600,
Abcam Biochemicals, Cambridge, MA, USA) or mouse-
anti-Pax7 antibody (1:50, Hybridoma Bank, Iowa City,
IA, USA). The sections were then incubated with the
goat-anti-rabbit CyTm5-conjugated or goat-anti-mouse
Cy3-conjugated secondary antibody (Jackson Lab) for
1 hr at RT. Slides were counterstained with DAPI dye
(1:800, Sigma, St Louis, MO, USA), rinsed and cover-
slipped with fluorescence mounting medium (Dako,
Glostrup Denmark). Stained sections were examined
under the Olympus fluorescence microscope (Olympus,
Center Valley, PA, USA), and digital images of sections
were acquired with a CCD camera.
Statistical analysis
Quantitative data were presented as a means ± standard
deviation (SD). A normal distribution of the samples
was confirmed and a student’s t-test (assuming equal
variances) was performed to determine the statistical
significance between two experimental groups. A P
value less than 0.05 was considered to be statistically
significant.
Results
Transplanted GFP-labeled myoblasts display different
engraftment pattern in mice with different immune
backgrounds
In the FLI study, we initially investigated the dynamic
engraftment of GFP-labeled myoblasts in TA muscles
of mdx and immunodeficient nude mice groups for
11 weeks after transplantation. The results revealed that
during the first 6 weeks fluorescent signals showed simi-
lar changes in the two groups. The TA muscle exhibited
its highest fluorescent intensity just after transplantation.
Following transplantation, the fluorescent intensity de-
creased by more than 80% compared to the highest
value at 72 h. Then it increased rapidly in the following
week, and gradually declined thereafter. After 6 weeks,
the intensity remained basically stable in the immunode-
ficient group, at around 23% of its original value. In con-
trast, in immunocompetent mdx mice, the fluorescent
intensity further weakened to less than 6% of the original
value at week 11, suggesting that the immunological re-
jection response of the host probably played a role in the
loss of transplanted myoblasts (Figure 1A-C). This re-
sponse may be triggered either by GFP or by dystrophin
(the latter of which would be regarded as a transgene to
the mdx mouse).
Figure 1 Dynamic engraftment of transplanted GFP-labeled myoblasts in tibialis anterior (TA) muscle of mdx and nude mice shown by
in vivo fluorescent imaging. The last picture in A and B is the bright-field photo. (A) A representative of dynamic TA muscle imaging in mdx
mouse. (B) A representative of dynamic TA muscle imaging in nude mouse. (C) Quantitative data of the GFP fluorescence intensity in mdx and
nude mice. PM, GFP-labeled primary myoblast. n = 6.
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of the immunogenic role of GFP
To assess the effect of allogenic protein GFP on the sur-
vival of transplanted myoblasts, we used mdx-GFP hybrid
mice. This strain was produced by crossing male mdx with
female C57BL/Ka-β-actin-EGFP mice and genotyped be-
fore experiment. In this animal model, we transplanted
wild type myoblasts passaged in vitro for the same genera-
tions as the GFP-modified ones into TA muscles. It
excluded the immuno-rejection effect of GFP and was
termed reverse transplantation. After one and two months,
muscle samples were harvested, and the presence of dys-
trophin was measured by immunohistochemistry. The dys-
trophin positive fibers usually displayed a weak green color
due to fusion with the GFP positive host fibers in the mdx-
GFP hybrid mice. In the mdx mice, the dystrophin positive
fibers generally overlapped with the GFP-labeled cells
(Figure 2A, B), and a relatively denser infiltration of inflam-
matory cells could be observed around the dystrophin
positive fibers (data not shown). Data showed that at two
months after transplantation, mdx-GFP hybrid mice exhib-
ited 2.9 fold higher levels of dystrophin positive fibers than
mdx mice (257.6 ± 166.8 versus 88.7 ± 75.2) (Figure 2C).
Transplanted GFP-labeled myoblasts engraft much better in
the TA muscle of C57BL/6 mice than in other mice strains
To explore the more suitable experimental host for the
GFP-labeled cells, we further investigated the survivalrate and engraftment efficiency of GFP-labeled myo-
blasts in C57BL/6 and BALB/c WT mice. Previous
tumor cell inoculation study indicated that the immuno-
genicity of GFP is very low in C57BL/6 mice [21]. When
transplanted with the same number of myoblasts (5 × 105)
into the TA muscles, the fluorescence intensity of the TA
muscles in C57BL/6 mice was significantly higher than
that in the BALB/c and mdx mice, and slightly lower than
that in the nude mice at one, two and three months after
transplantation. Compared with the original value, the
fluorescence intensity in all groups significantly de-
creased one month post-transplantation. However, C57BL/
6 mouse model maintained much higher and stable level
of fluorescence intensity throughout the experiment, sug-
gesting that the GFP-labeled myoblasts were minimally
rejected in these animals. C57BL/6 mouse, therefore has
been considered a favorable animal model for research on
GFP-labeled cells transplantation (Figure 3).
Myoblasts from the GFP-transgenic mouse exhibit much
stronger engraftment capability than that from virally
GFP-transduced ex vivo
Next, we evaluated the impact of the GFP-labeled myo-
blasts derived from different sources on their survival
and integration after transplantation in the C57BL/6 mice.
Using FLI, we examined the cell behavior of transplanted
myoblasts that were obtained either from the GFP trans-
genic mice or, alternatively, from in vitro transfection with
Figure 2 Dystrophin immunostaining (red) showing the engraftment of transplanted myoblasts in dystrophin-deficient mice. A TA
muscle was injected with 5 × 105 cells and harvested 2 months after transplantation. (A) TA muscle of mdx mouse injected with GFP-labeled
myoblasts. (B) TA muscle of GFP transgenic-mdx hybrid mouse injected with non-labeled myoblasts. (C) Merged image of A with GFP. (D) Merged
image of B with GFP. Scale bar = 20 μm. (E) Levels of dystrophin-positive fibers in TA muscle of mdx mouse injected with GFP-labeled myoblasts
(bar A) and of GFP transgenic-mdx hybrid mouse injected with non-labeled myoblasts (bar B). Values are mean ± standard errors of 5 samples.
(*P < 0.01; Student’s t-test).
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tensities of the GFP-labeled myoblasts were measured in
multi-well culture plates and the intensity of the equal
number of cells was standardized for in vivo fluorescence
imaging. Cell viability of myoblasts from GFP transgenic
mice was significantly higher than cells obtained through
the GFP-lentiviral transfection. After transplantation, GFP-
labeled myoblasts from transgenic mice presented a
stronger fluorescent signal over a wider area, especially at
month one and two (Figure 4A, B).
These data were further confirmed by analyzing the
fluorescence signal of the muscle tissue sections. The green
muscle fibers derived from myoblasts of GFP transgenic
mice displayed a wider distribution and were more uni-
form in morphology one month post-transplantation, indi-
cating that myoblasts from GFP-transgenic mice display
higher differentiation potential. In contrast, many smallFigure 3 Fluorescence intensities of TA muscles in of nude,
C57BL/6, BALB/c and mdx mice. *P < 0.01, Values are mean ±
standard errors of 5 samples.and medium-sized cells with green fluorescence could still
be observed in the GFP-lentivirus transfection group dur-
ing the first two months (Figure 4C).
GFP-transduced myoblasts not only display myogenic
differentiation but produce donor-derived satellite cells
after transplantation
To evaluate the myogenic differentiation potential of
GFP-transduced myoblasts, and especially their capabil-
ity to generate donor-derived precursor cells of trans-
planted myoblasts, we examined the engraftment of
GFP-labeled cells in TA muscles of immunodeficient
nude and C57BL/6 mice by immunofluorescent histo-
chemistry two months after transplantation. Results
showed that when transplanted with 5 × 105 myoblasts,
hundreds of skeletal muscle fibers marked with GFP
could be observed in TA muscles. The engrafted fibers
were similar in size to the recipient and displayed green
color in various shades based on how they fused with the
host fibers. Very few centrally-located nuclei myofibers
were observed at that time point. We detected small
GFP-positive cells, redistributed in the microenviron-
ment of satellite cells between the basement membrane
and myofiber. These cells expressed satellite cells-specific
marker, Pax7, indicating that the grafted GFP-labeled
myoblasts could not only differentiate to form myofibers,
but also reenter in in situ niche to constitute a stored
stem cell pool (Figure 5).
Discussion
Longitudinal follow-up of the fate of transplanted cells
or transgene expression is critical for cell transplant-
ation and gene therapy research. In recent years, in vivo
Figure 4 The effect of different origin of GFP-labeled myoblasts on the engraftment in C57BL/6 mice. (A) Representative dynamic TA
muscle imaging of GFP-labeled primary myoblasts from transfected in vitro (PM-GFP) and from GFP transgenic mouse (GFP-PM). (B) Fluorescence
intensity levels of the PM-GFP and GFP-PM. Data represent means and standard errors of 6 samples; *P < 0.01. (C,D) Histological examination of
the TA muscle 1 month after transplantation with PM-GFP (upper panel) and GFP-PM (lower panel). Scale bar = 100 μm.
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has gradually become one of the most favorable strat-
egies for such studies [1,11,30,31]. Several types of mu-
tant GFP with good stability and enhanced fluorescent
brightness have already been commercialized. The en-
hanced GFP (eGFP) gene in the present study is under
the control of the promoter of the conservative actin
gene, its fluorescent intensity is kept stable during theFigure 5 Histological evidence of transplanted myoblast-derived sate
and cryo-sectioned in 10 μm sections. (A) Green channel image shows the
shows 2 positive cells. (C) DAPI staining show the nuclei of all cells in this
myoblast-derived satellite cell, arrowhead indicates a satellite of the host. Sculture process and after in vivo transplantation. In a
previous study, we monitored the dynamic process of
skeletal muscle regeneration by transplanting EGFP-
labeled myoblasts in severe combined immune defi-
ciency (SCID) mice, and verified high sensitivity and
reliability of this experimental approach [32]. However,
determining the potential impact of GFP on the cell en-
graftment and optimizing the strategy for GFP-basedllite cells. The TA muscle was harvested 1 month after transplantation
eGFP-labeled transplanted cells. (B) Anti-Pax7 immunostaining (red)
area. (D) Merged image of A, B and C. Arrow indicates a transplanted
cale bar = 20 μm.
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models, still remains a challenge.
As an exogenous protein, GFP marker was documented
to be immunogenic [12,14,15]. In the present study, we ob-
served the dynamic processes of transplanted GFP-labeled
myoblasts in mice with different immunological back-
grounds, as well as reverse transplantation of normal non-
labeled myoblasts into mdx-GFP hybrid mice. Our results
not only highlighted the immunogenic role of GFP, but also
offered a way to assess the effect of transgene (dystrophin)
on the survival of transplanted myoblasts.
In optical molecular imaging, consistent expression of
the reporter gene is an important prerequisite for the
tracking of transplanted living cells. However, the GFP
itself was always immunorejected in the immunocompe-
tent host as an exogenous protein. Skelton et al. first re-
ported that GFP was less immunogenic to C57BL/6
mice in which the GFP-transduced EL-4 lymphoma cells
could form subcutaneous tumors. However, they hy-
pothesized that this phenomena might be an exception
to the rule because the GFP-labeled tumors were rarely
noted in other animals or relative species [21,22]. Our
study showed that the fluorescent intensity of GFP-
labeled myoblasts after transplantation in C57BL/6 mice
was higher than that found in BALB/c and mdx mice,
similar to the levels detected in nude mice, confirming
that the GFP-transduced myoblasts were only minimally
rejected in C57BL/6 mice. To our knowledge, this is first
report suggesting that the GFP-transduced stem cells en-
graft better in C57BL/6 mice than in other species.
Furthermore, low rejection rate of GFP-transduced myo-
blasts in this animal model means that there is no need for
additional immunosuppressive agents that may potentially
disturb the tissue homeostasis. We suggest therefore, that
C57BL/6 mice are a more suitable host animal model for
studies that require GFP-labeled stem cells tracking.
In addition to the early massive cell death, host versus
graft reaction (HVGR) is a critical determinant of the
success of cell transplantation. On condition that a re-
cipient’s genetic background and major histocompatibil-
ity are coincident with the donor’s, the immunological
response of hosts depends mainly on the structure and
the dose of exogenous protein, the route of entry, the
type of cells expressing the transgene as well as the viral
vector system [16,33,34]. In the present study, we show
that transplanted myoblasts from GFP-transgenic mice
have better engraftment capacity comparing to ex vivo
transfection. We used lentivirus vector to obtain ex vivo
GFP-transduced myoblasts and obtained highly purified
GFP-labeled cells using drug-resistance gene screening
and flow cytometry sorting. GFP-labeled myoblasts were
also isolated and cultured from transgenic mice in which
the GFP gene was stably integrated into the genome at em-
bryonic stage. This method allowed to avoid issues relatedto the immunogenicity and virulence of the viral vector in
the virus-based transfection. It also didn’t have any related
toxicity associated with viruses, and thus did not perturbed
gene delivery. Consistent with this, studies from Ghaziza-
deh group indicated that re-transplanting in vitro GFP
transfected keratocytes into the host significantly reduced
the immune reaction compared with direct injection of the
GFP gene, a phenomenon that may be attributed to the
lack of the extra antigen brought by in vivo injection of the
viral vector [35]. Recently, another study demonstrated that
the vector-associated inflammation was reduced through
ex vivo gene delivery in lung transplantation [36].
In summary, by combining the use of in vivo FLI, hist-
ology and immunohistochemistry, we not only demon-
strated the immunogenicity of GFP reporter during cell
transplantation, but more importantly, provided opti-
mized conditions for GFP-based tracking using in vivo
FLI. We also demonstrated that the immunocompetent
C57BL/6 mouse is a better transplant recipient as it shows
only minimal immunological rejection of GFP, and GFP
transgenic mice appear to be a are better quality cell
source than the in vitro transfected ones due to their abil-
ity to circumvent the immune response to the vector.
Conclusions
GFP reporter has a distinct immunogenic effect in im-
munocompetent animal host during cell transplantation.
Among several mouse models, C57BL/6 mouse is clearly
a better transplant recipient with only minimal immuno-
logical rejection of GFP. It appears that GFP transgenic
mice are able to evade the immune response to the vec-
tor, and therefore, may be considered a better quality cell
source, while the use of in vivo FLI provides optimal
conditions for GFP-based cell tracking and can poten-
tially be extrapolated in human biomedical research.
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